OCX Oncocyte

Oncocyte Corporation Hosting Key Opinion Leader Call on Proprietary Molecular Tests for Cancer Treatment Selection

Oncocyte Corporation Hosting Key Opinion Leader Call on Proprietary Molecular Tests for Cancer Treatment Selection

Physician researchers from Yale Cancer Center and University of California San Francisco (UCSF) to present on test performance in immunotherapy and chemotherapy selection

IRVINE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that the Company will host a key opinion leader (KOL) call on the Company’s proprietary DetermaRx™ and DetermaIO™ molecular tests for cancer treatment selection on Tuesday, December 15, 2020 at 11:00am Eastern Time.

The call will feature a presentation by Key Opinion Leaders (KOLs) Johannes Kratz, MD, FACS (University of California at San Francisco) who will discuss the clinical opportunity for DetermaRx™, the first and only test for adjuvant treatment selection in surgically resected lung cancer patients, which is Medicare-reimbursed, and Lajos Pusztai, MD, DPhil (Yale Cancer Center) who will discuss clinical evidence supporting DetermaIO™, Oncocyte’s gene expression test to predict response to first and second generation immunotherapies, including currently marketed immune-checkpoint inhibitors (ICIs). Close to 750,000 patients are eligible for ICI treatment annually in the United States alone. Dr. Pusztai and members of the Oncocyte management team, including Chief Medical Officer Doug Ross, MD, PhD, will be available to answer questions following the formal presentations.

Oncocyte's management team will also give an overview of their Determa RNA Platform strategy for cancer content to assist in critical clinical questions that today are unanswered. They will also provide an update on the commercialization strategy for both DetermaRx™ and DetermaIO™, two of the Company’s initial growth engines from the Determa Platform approach. These two products together have an estimated Served Available Market of well over $3 billion, and the launch of DetermaRx and anticipated clinical launch of DetermaIO will be the primary growth drivers for 2021 as the Company continues to ramp up revenues and reduce overall burn. Importantly, the clinical questions answered by these two proprietary approaches have already saved lives and reduced the cost of care, two paramount imperatives of Oncocyte’s Mission.

To for the call, click .

Dr. Johannes Kratz is a thoracic surgeon who specializes in treating disorders of the trachea, chest wall, lung, esophagus and mediastinum. He directs UCSF's program for advanced minimally invasive and robotic thoracic surgery. Kratz earned his medical degree at Harvard Medical School, graduating Magna Cum Laude. He completed a general surgery residency at Massachusetts General Hospital, followed by a fellowship in cardiothoracic surgery at UCSF. He also has a master's degree in philosophy from Stanford University. Kratz is a member of the American College of Surgeons, Society of Thoracic Surgeons, Massachusetts Medical Society and American Society of Clinical Oncology. In 2017, he received a UCSF Health Exceptional Physician Award. He is the Van Auken Endowed Chair in Thoracic Oncology at UCSF. Kratz's research interests include robotic surgery outcomes, lung and esophageal cancers, biomarkers to personalize lung cancer treatment and immunotherapies for thoracic tumors. His current research focuses on understanding the molecular and genetic profiles of high-risk tumors in early stages and developing targeted therapies to treat them.

Dr. Lajos Pusztai is Professor of Medicine at Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program. Dr. Pusztai is also Chair of the Breast Cancer Research Committee of the South West Oncology Group (SWOG). He received his medical degree from the Semmelweis University of Medicine in Budapest, and his D.Phil. degree from the University of Oxford in England. Dr. Pusztai has published over 250 scientific manuscripts in high impact medical journals including the NEJM, JAMA, Journal of Clinical Oncology, Nature Biotechnology, PNAS, Lancet Oncology and JNCI. He is among the top 1% most highly cited clinical investigators in medicine over the past 10 years according to a 2015 Thomson Reuters report. He is Associate Editor of the Journal of National Cancer Institute (JNCI), member of the Scientific Advisory Board of the Breast Cancer Research Foundation, former member of the NCI North American Breast Cancer Steering Committee and Co-Chair of the Trans-ALTTO Committee and Chair of the Data Safety Monitoring Committee of the OPTIMA trial in the United Kingdom.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. The Company also plans to launch monitoring tests including Therasure™-CNI MONITOR, a blood-based immune therapy monitoring test, as a research use tool in 2021. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.

Investor Contact

Bob Yedid

LifeSci Advisors, LLC

646-597-6989

Media Contact

Cait Williamson, Ph.D.

LifeSci Communications, LLC

646-751-4366



EN
07/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transpl...

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced...

 PRESS RELEASE

Insight Molecular Diagnostics Announces Positive Strategic Update and ...

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database 5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd-cfDNA)Novel registry expected to collect approximately 50,000 samples over three years for organ rejection assay combining both percent and total donor derived cell-free DNA into one scoreRegistry expected to assess utility of “the Berlin protocol” of accelerated...

 PRESS RELEASE

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcome...

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it is actively enrolling patients in its clinical trial to assess GraftAssureDx and that last week, it enrolled the first patient. In addition, now names 10 leading transpl...

 PRESS RELEASE

iMDx to Participate in NYC Investment Conferences September 8 - 11

iMDx to Participate in NYC Investment Conferences September 8 - 11 NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8 – 9, 2025Location: In-person at the Lotte New York Palace Hotel and virtual Format: Company presentation on Monday, September 8 at 5:00 pm ET, and one-on-one meetingsLink t...

 PRESS RELEASE

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we have ever been to deli...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch